Kymera Therapeutics Reports Q1 2026 Results: Strong Pipeline Progress, Major Milestones, and Robust Cash Position

Key Highlights from Kymera Therapeutics’ First Quarter 2026 Financial and Business Update

Pipeline Progress and Clinical Milestones

• KT-621 (STAT6 Degrader):
  • Two parallel Phase 2b trials ongoing:
    • BROADEN2 for atopic dermatitis (AD), expanded in January 2026 to include adolescents (ages 12-75), with data expected by mid-2027.
    • BREADTH for eosinophilic asthma, dosing commenced January 2026, with data anticipated late 2027.
  • FDA granted Fast Track designation for moderate to severe eosinophilic asthma in April 2026, adding to prior Fast Track for AD.
  • Positive Phase 1b data in AD presented at AAD Annual Meeting, showing deep STAT6 degradation, significant biomarker reductions, encouraging clinical activity, and a strong safety profile.
  • GLP chronic toxicology studies in rats and non-human primates (NHP) completed with no adverse findings.
  • Upcoming presentations at major medical conferences in May 2026 (SID and ATS), highlighting STAT6 modulation and potential to transform respiratory care.
• KT-579 (IRF5 Degrader):
  • First-in-class, oral IRF5 degrader targeting autoimmune diseases (lupus, RA, Sjögren’s, IBD).
  • Phase 1 trial in healthy volunteers ongoing since February 2026; first data expected in 2H26.
  • Preclinical studies show KT-579 is as or more efficacious than current small molecule inhibitors and biologics, with no adverse effects seen at any dose.
  • Upcoming preclinical data presentations at Digestive Disease Week (IBD focus) and EULAR/FOCIS (lupus focus) in May and June.
• Partnered Programs:
  • April 2026: Gilead Sciences exercised its option to exclusively license KT-200 (oral CDK2 molecular glue degrader), triggering a \$45 million milestone payment due in Q2 2026. IND planned for 2027. KT-200 targets breast cancer and other solid tumors.
  • KT-485/SAR447971 (oral IRAK4 degrader, partnered with Sanofi): IND-enabling studies completed, clinical entry expected in 2026.
• Research:
  • Kymera expects to nominate at least one new first-in-class oral development candidate in 2026, leveraging its expertise in targeted protein degradation.

Financial Performance and Position

• Collaboration Revenue: \$34.4 million in Q1 2026 (up from \$22.1 million in Q1 2025), entirely from the Gilead partnership.
• Research and Development Expenses: \$98.2 million in Q1 2026 (up from \$80.3 million in Q1 2025), reflecting increased investment in STAT6, platform, discovery programs, and R&D growth. Stock-based compensation in R&D: \$8.6M (2026) vs \$7.5M (2025).
• General and Administrative Expenses: \$20.4 million in Q1 2026 (up from \$16.3 million in Q1 2025), mainly due to legal/professional fees and company growth. Stock-based compensation in G&A: \$7.4M (2026) vs \$6.7M (2025).
• Net Loss: \$69.2 million in Q1 2026 (vs. \$65.6 million in Q1 2025).
• Cash, Cash Equivalents, and Marketable Securities: \$1.55 billion as of March 31, 2026, providing a cash runway into 2029 and covering multiple anticipated clinical milestones.
• Weighted Average Shares Outstanding: 97.5 million (Q1 2026), up from 80.1 million (Q1 2025).

Strategic and Shareholder-Relevant Developments

• Gilead Option Exercise: The \$45 million milestone upon Gilead exercising its KT-200 option is a significant near-term cash infusion and validates Kymera’s discovery platform. This partnership progress is likely to be viewed positively by investors and may be price sensitive.
• Multiple Fast Track Designations for KT-621: These regulatory milestones de-risk the program and could accelerate development timelines, increasing potential asset value.
• Strong Cash Position: The \$1.55 billion cash runway into 2029 covers all planned milestones, reducing financing risk and supporting continued aggressive pipeline investment.
• Upcoming Data Readouts and Conference Presentations: Key clinical milestones for KT-621 and KT-579, and high-profile medical conference presentations, could act as catalysts for share price movement, especially as topline data approaches for major indications.
• Pipeline Breadth and Innovation: Kymera’s ability to advance multiple first-in-class oral protein degraders, both internally and through partnerships, positions the company as an industry leader in targeted protein degradation, a field of growing strategic interest.

Upcoming Events

• Kymera will host a video conference call and webcast on April 30, 2026, at 8:30 a.m. ET to discuss these results and updates. Replay will be available on the company website.
• Multiple scientific presentations scheduled for May and June 2026 at leading conferences (SID, ATS, DDW, EULAR, FOCIS).

About Kymera Therapeutics

Kymera Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation (TPD) to develop oral small molecule medicines for diseases with high unmet need, especially in immunology. The company, founded in 2016 and recognized as one of Boston’s top workplaces, has advanced the first degrader into the clinic for immunological diseases and maintains a robust pipeline and partnership network.

Disclaimer:

This article is provided for informational purposes only and does not constitute financial or investment advice. All statements regarding clinical development, financial projections, and future events are based on publicly available disclosures as of the publication date and may be subject to change. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. This article contains forward-looking statements that involve a number of risks and uncertainties which may cause actual results to differ materially from those anticipated.

View Kymera Therapeutics, Inc. Historical chart here